Heme oxygenase-1 (HO-1) catalyzes the rate limiting reaction of heme metabolism and plays critical roles in resistance to oxidative stress and other cellular functions. It is well known that HO-1 is induced in response to various stresses; however, the signaling pathways involved remains incompletely elucidated. Acrolein is an alpha, beta-unsaturated aldehyde present in cigarette smoke and also a product of lipid peroxidation. In this investigation we studied HO-1 induction in response to acrolein and determined the signaling pathways involved in human bronchial epithelial cells (HBE1 cells). We demonstrated that acrolein significantly increased the HO-1 mRNA content and promoter activity. Acrolein-mediated HO-1 induction was significantly attenuated by pan-PKC inhibitors RO318220, staurosporine, and PKC-δ selective inhibitor rottlerin and PKC-δ siRNA. The HO-1 induction was also decreased by PI3K inhibitors LY294002 and wortmannin. No significant effects on HO-1 induction were observed with the pretreatment of MAPK pathway inhibitors PD98059 (ERK), SB203580 (p38MAPK) and JNKi, and conventional and atypical PKC inhibitors. Furthermore, Nrf2 silencing significantly attenuated the HO-1 induction by acrolein. Inhibition of PKC-δ significantly decreased acrolein-mediated Nrf2 nuclear translocation, though inhibition of PI3K had no effect.
Introduction
Heme oxygenase (HO) is the rate-limiting enzyme that catalyzes the degradation of heme into iron, biliverdin and carbon monoxide. By doing so, HO is not only involved in heme metabolism and erythrocyte turnover, it also plays cytoprotective roles against oxidative injuries and inflammation. Among the three isoenzymes of HO identified so far, HO-1 is the only isoform that can be induced in response to stimuli such as oxidants, hypoxia, heavy metals, and inflammatory molecules (1) . Accumulating evidence from both in vivo and in vitro experiments suggest that HO-1 plays critical roles in cellular functions such as adaptation to stress, cellular proliferation, and apoptosis (2) . Recently HO-1 has also been implicated in various pathologies including neurodegenerative diseases (3, 4) , cardiovascular diseases (5) , and pulmonary diseases (6, 7) .
HO-1 induction in response to environmental stress has been being extensively studied. The induction occurs mainly at the transcriptional level. Several DNA cis-elements present in the promoter (5'-flanking) region of HO-1 gene, including AP-1 binding sites, electrophile response element (EpRE), stress response element (StRE), cAMP response element, and NF-κB binding sites, have been associated with the induction of HO-1 gene (1). Among them, EpRE and its binding protein Nrf2 have been studied extensively. Nrf2 is a basic leucine zipper protein (bZIP) belonging to the cap 'n' collar (CNC) family of transcription factors and is a well-established player in EpRE signaling. Under basal conditions, Nrf2 is retained in the cytosol through association with Kelch-like ECH-associated protein 1 (Keap1). Upon exposure to oxidative stimuli, Nrf2 is dissociated from Keap1 and translocated into the nucleus, where it forms heterodimers with other bZIP-CNC factors such as small Maf proteins and binds to EpRE to regulate gene transcription (for recent reviews see (8) (9) (10) ). Recent studies have shown that Nrf2/EpRE activation is essential for HO-1 induction in response to stimuli, especially those linked with oxidative/electrophile stress (11) (12) (13) (14) (15) (16) (17) (18) (19) .
Several signaling pathways, including ERK, p38 mitogen-activated protein kinase (MAPK), c-Jun N-terminal kinase (JNK), protein kinase C (PKC), and phosphatidylinositol 3-kinase (PI3K), have been implicated in HO-1 induction (1). It remains unclear how these signaling kinases works. Recent reports suggest that these pathways may increase HO-1 transcription through regulating Nrf2/EpRE activity (20, 21) . Indeed, the phosphorylation of Nrf2 is critical for Nrf2-Keap1 dissociation (22, 23) and Nrf2 nuclear exportation (24) , and in some research models, inhibition of above signaling pathways led to the decrease of Nrf2 nuclear translocation (25) .
Acrolein is a highly reactive α,β-unsaturated aldehyde present in cigarette smoke, vehicle exhaust, and over-heated cooking oil or food (26) ; it also occurs as a lipid peroxidation product (27) and a metabolic by-product of allyl alcohol, allylamine, spermine, spermidine, and the antineoplastic drug cyclophosphamide (26) . Acrolein concentration is increased in various oxidative stress-implicated diseases such as arteriosclerosis (28) and Alzheimer's disease (29) . At higher concentration, acrolein is very toxic and causes injuries by conjugating to proteins and nucleic acids, and disrupting normal cellular function (26) .
Recently several studies suggest that at subtoxic concentration, acrolein could activate a variety of signaling pathways and regulate the expression of cytoprotective genes (30) . In this study we investigated the HO-1 induction by acrolein and determined the signaling pathways involved in human bronchial epithelial cells with the aim of further understanding the regulatory mechanism of HO-1 induction.
Methods and materials

Chemicals and reagents
Unless otherwise noted, all chemicals were from Sigma (St. Louis, MO). Antibodies and small interfering RNAs were from Santa Cruz (Santa Cruz, CA). Protein kinase inhibitors were bought from Calbiochem (La Jolla, CA). TRIzol Reagent was from Life Technologies (Grand Island, NY). DNA-free reagent was from Ambion (Austin, TX).
TaqMan Reverse Transcription Reagent and SYBR Green PCR Master Mix were from Applied Biosystems (Foster City, CA). Luciferase activity assay kit was from Promega (Madison, WI). FuGENE 6 transfection reagent was from Roche (Indianapolis, IN). M-PER mammalian protein extraction reagent and NE-PER nuclear extraction reagents were from Pierce (Rockford, IL). All chemicals used were at least analytical grade.
Cell culture and treatment
A human bronchial epithelial cell line (HBE1 cell) was cultured in collagen-coated dishes in 5% CO 2 at 37 o C as described by Harper et al. (31) . Cells were treated when 90% confluent. Acrolein was freshly diluted to appropriate concentrations with 1XPBS before use.
HO-1 mRNA assay
The content of HO-1 mRNA was determined with real-time RT-PCR method by following the protocol described before (32) . Briefly, RNA samples were treated with DNA-free reagent and reverse transcribed by using the TaqMan reverse transcription system, real-time PCRs were then performed with a Cepheid 1. 
Western Blotting
Western blotting was performed as described previously (33) . Briefly, protein was 
Statistical Analysis
The comparative ∆∆C T method was used for the relative mRNA quantitation as described before (25) . All data were expressed as the mean ± standard error. Sigma Stat software was used for statistical analysis and statistical significance was accepted when p < 0.05.
The Tukey test was used for comparison of mRNA level and luciferase activity.
Results
Acrolein induces HO-1 transcription in HBE1 cells
Acrolein can be lethal but at subtoxic doses, it is a potent signaling agent that can affect 
. This data suggest that acrolein-increased HO-1 mRNA in dose-dependent manner.
The HO-1 mRNA increase upon acrolein exposure was also time-dependent, the increase became significant since 6 h and remained at 24 h, but the maximal increase occurred at 12 h of acrolein exposure (data not shown).
To determine whether acrolein increases HO-1 expression at the transcription level, the effect of acrolein on HO-1 promoter activity was investigated with a reporter assay. The activation of HO-1 promoter was studied by using a luciferase reporter that was driven by a 4.9 kb proximal region of the human HO-1 promoter (34) . As shown in Figure 1C , the HO-1 promoter activity was increased by acrolein in a dose-dependent manner, and it was increased as high as 5.2 fold by 20 µM acrolein. Taken together, data in Figure 1B and Figure 1C reveal that acrolein up regulated HO-1 expression at the transcription level. Since the induction of HO-1 was more significant with 20 µM acrolein treatment, 20 µM acrolein was used in the following experiments.
MAPK pathways are not involved in HO-1 induction by acrolein
The three major MAPK pathways, i.e. ERK1/2, p38MAPK, and JNK, have been suggested to be involved in the regulation of HO-1 by a variety of agents. Using specific inhibitors against these pathways, we investigated the involvement of MAPKs in acrolein-mediated HO-1 induction in HBE1 cells. At concentrations that effectively inhibit targeted pathways (32), PD98059, SB203580, and JNK inhibitor I, specific inhibitors of ERK1/2, p38MAPK, and JNK pathways respectively, had no significant effect on HO-1 mRNA level that was increased by acrolein (Figure 2A ), suggesting that ERK, JNK, and p38MAPK pathways were not involved in HO-1 induction by acrolein.
Both PKC and PI3K pathways are involved in HO-1 induction by acrolein
We then investigated the involvement of PKC and PI3K pathways in acrolein-mediated HO-1 induction. As shown in Figure 2B , HO-1 induction was inhibited by pan-PKC inhibitor RO318220 (2 µM) by 70% and staurosporin (0.2 µM) by 65%, respectively.
Meanwhile, PI3K inhibitors LY294002 (50 µM) and wortmannin (0.5 µM) also partially inhibited the HO-1 induction (by about 50% and 58%, respectively) ( Figure 2B ).
Considering the partial inhibitory effects of PKC and PI3K inhibitors, we examined whether the use of both simultaneously would block the HO-1 induction more effectively. Pretreatment with 2 µM RO318220 and 50 µM of LY294002 in combination abrogated the increase of HO-1 mRNA content ( Figure 2B ), suggesting that PKC and PI3K act through separate pathways to regulate HO-1 expression.
The involvement of PKC and PI3K signaling pathways in HO-1 induction was further studied with the HO-1 reporter assay. Consistent with their effects on mRNA level, pan-PKC inhibitors RO318220 (2 µM), PI3K inhibitors LY294002 (50 µM) and wortmannin (0.5 µM), also significantly decreased the activation of HO-1 promoter by acrolein ( Figure 2D ). In addition, combined pretreatment with both RO318220 and LY294002
completely blocked the activation of HO-1 promoter. Taken together, these data suggest that both PKC and PI3K signaling pathways are involved in the acrolein-mediated HO-1 induction; it also suggests that PKC and PI3K trigger HO-induction through separate downstream molecules.
PKCs are a family of kinases that include three subfamilies of isozymes, i.e., classical or conventional PKC (cPKC: α, β, γ), novel PKC (nPKC: δ, ε, θ and η), and atypical PKC (aPKC: ζ and ι/λ). To investigate which PKC isozymes are responsible for acroleinmediated HO-1 induction, we also determined the effects of relatively specific inhibitors against PKC isozymes on HO-1 mRNA induction. cPKC inhibitors RO31-8425 and RO32-0432, and a pseudosubstrate peptide inhibitor of the aPKC, did not decrease HO-1 mRNA induction. In contrast, rottlerin, a PKC-δ inhibitor, increased the basal level of HO-1 mRNA, but significantly attenuated acrolein-mediated HO-1 mRNA induction (37 fold vs 4.5 fold) ( Figure 2C ). As shown in Figure 2D , rottlerin did not affect the basal activity of HO-1 reporter driven by a 4.9kb bp of DNA sequence from the upstream of 5'-untranslated region of human HO-1 gene, but it decreased acrolein-mediated promoter activity by 58%. suggesting that PKC-δ is responsible for acrolein-increased HO-1 mRNA.
To avoid any non-specific effect of rottlerin and further confirm the involvement of PKC-δ in HO-1 induction, effect of PKC-δ siRNA on acrolein-mediated HO-1 induction was investigated. PKC-δ protein was decreased by 56% with the treatment of siRNA for 25h
( Figure 3A) . Meanwhile, PKC-δ siRNA decreased HO-1 mRNA induction ( Figure 3B) and HO-1 promoter activation ( Figure 3C ) by about 25%, and 33%, respectively, indicating that PKC-δ is involved in acrolein-mediated HO-1 induction.
Nrf2/EpRE is involved in HO-1 induction by acrolein
Many transcription factors including AP-1, NF-κB, and Nrf2 have been implicated in HO-1 induction by other agents. To test the hypothesis that Nrf2 is involved in acroleininduced HO-1 expression, we investigated the effect of Nrf2 silencing on HO-1 induction.
Nrf2 siRNA (50 nM) markedly decreased Nrf2 protein levels in both the cytosol and nucleus, and a more significant effect was observed in nuclear Nrf2 with acrolein treatment ( Figure 4A ). Nrf2 siRNA significantly attenuated acrolein-increased HO-1 mRNA ( Figure 4B ) and promoter activity ( Figure 4C ). These data suggest Nrf2 is a crucial transcription factor involved in HO-1 induction by acrolein.
Effects of PKC-δ and PI3K inhibitors on Nrf2 nuclear accumulation
Based on data above that suggested PKC-δ, PI3K, and Nrf2 were involved in HO-1 induction, and that PKC was reported to be involved in Nrf2 activation, we examined whether acrolein activates Nrf2 via PKC-δ and PI3K pathways. Nrf2 is located in the cytoplasm at basal conditions and upon stimuli, translocates into the nucleus to play its role as transcription factor. The nuclear accumulation of Nrf2 is usually considered a marker of Nrf2 activation in response to stressors. As shown in Figure 5 , 1 h treatment with 20 µM acrolein increased nuclear Nrf2 significantly (about 2.5 fold) compared with non-treatment in HBE1 cells. Pretreatment with PKC-δ inhibitor (rottlerin) for 1h abrogated acrolein-caused Nrf2 nuclear translocation, while PI3K inhibitor (LY294002) had no effect on Nrf2 activation at concentration that inhibited HO-1 induction, suggesting that PKC-δ is but PI3K is not involved in the activation of Nrf2. PKC is a family of at least 11 isozymes and our data strongly suggest that PKC-δ is the PKC isozyme responsible for acrolein-induced HO-1 expression ( Figure 2C, 2D and 3 ).
The effect of PKC-δ inhibitor rottlerin on HO-1 induction appeared to be more potent compared with that of PKC-δ siRNA. The former decreased the HO-1 mRNA induction by 87% and promoter activity by 60%, respectively, while the latter decreased the HO-1 promoter activation by 33% and mRNA by 25 %. Nonetheless, the apparently lesser potency of PKC-δ siRNA was likely due to the lower efficiency of siRNA in deceasing PKC-δ protein than rottlerin was in decreasing activity as the maximal decrease of PKC-δ protein by its siRNA was only 60%. Taking this observation into consideration, the data from the application of rottlerin and siRNA were consistent. Together, the data clearly show that PKC-δ is partially involved in acrolein-mediated HO-1 induction in HBE1 cells.
In contrast with the effect on acrolein induced HO-1, results on the effect of PKC-δ inhibition on basal HO-1 expression revealed other aspects of the regulation of this gene.
although rottlerin increased basal expression of HO-1 mRNA ( Figure 2C ) at the transcriptional level (data not shown), it has no effect on the basal activity of the reporter driven by 4.9 kb base pair of DNA sequence from the upstream of the 5'-untranslated region of human HO-1 promoter, suggesting that rottlerin may work through activating cis-elements further upstream of the DNA sequence used in the reporter construct. One could also speculate equally that rottlerin increased HO-1 expression by inhibiting signaling for regulation of a suppressor element. The current evidence however, is circumstantial and the role of other elements is actually beyond the scope of the current study.
The involvement of PKC-δ in HO-1 induction was also previously observed in monocytes by curcumin (41) and endothelial cells by piceatannol (42) . There are also reports about the involvement of cPKC (43) and aPKC (44) (45) in HO-1 induction. In current study, however, the cPKC inhibitors RO31-8425 and RO32-0432, and aPKC pseudosubstrate inhibitor (peptide inhibitor against PKC-ζ) had no effect on HO-1 induction, neither they had effect on nuclear translocation of Nrf2 (data not shown),
indicating that these PKC isozymes are not involved in acrolein-mediated HO- In contrast to some studies, we did not find the involvement of MAPKs (ERK1/2, p38MAPK, and JNK) in HO-1 induction by acrolein (Figure 2A) . In a previous study, 
